Preischemic Neuroprotective Effect of @entity1214 and XXXX on Transient Cerebral Ischemic @entity35 Model.

@entity64 @entity1214 @entity2500 @entity2141 @entity1188 @entity40 @entity35 @entity17756
UNASSIGNED: We investigated the neuroprotective properties of single doses of @entity1214 and @entity17756 when administered prior to @entity64 . Male @entity35 were assigned randomly to one of the following groups: (1) control (Con) group (n=10), (2) @entity1214 (Mino) group (n=10), (3) @entity17756 (SO) group (n=10). @entity35 were treated with a single dose of @entity1214 or @entity17756 at 30min before @entity64 . A @entity2500 ( @entity2500 ) was made at 30min after drug administration and reperfusion was done. The @entity35 were subjected to a neurobehavioral test at days 1, 3 and 7 after @entity2500 . The cerebral ischemic volume was quantified by MetaMorph imaging software after TTC staining. The neuronal cell survival and astrocytes expansion were assessed by the @entity2141 and @entity40 immunohistofluorescence staining. Apoptosis was detected by the TUNEL assay. We statistically analyzed and compared the results with each other. Mino and SO groups had neuroprotective effect and showed a better behavioral performance of adhesive removal and treadmill test at 7 days after @entity64 . Mino and SO groups also showed a smaller @entity1188 volume than control group at 7 days after @entity64 . Immunohistofluorescence staining showed a higher number of @entity2141 positive cells, lower activated astrocytes in @entity40 and a lower apoptosis in TUNEL staining. This study showed that single doses of @entity1214 and @entity17756 prior to @entity64 had neuroprotective effects. These agents will be useful not only in post- @entity64 therapy but also in @entity64 prevention in several cerebrovascular procedures like carotid endarterectomy, bypass procedure, endovascular angioplasty, thromboembolectomy or thrombolysis.
